insights_auto
Bakit bumaba ang BH3 3.37%?
Tingnan ang Higit pang Detalyechevron_right
BH3:FRA
PTC Therapeutics, Inc.
€55.00
arrow_downward
-3.37%(-1.92) 1D
Okt 13, 10:00:00 PM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa BH3...
Buksan
€54.90
Mataas
€55.00
Mababa
€54.90
Mkt. cap
5.00B
Avg. na dami
0.00
Dami
0.00
Mataas nang 52-wk
€77.02
Mababa nang 52-wk
€52.50
Bilang ng mga empleyado
991
Buksan
€54.90
Mataas
€55.00
Mababa
€54.90
Mkt. cap
5.00B
Avg. na dami
0.00
Dami
0.00
Mataas nang 52-wk
€77.02
Mababa nang 52-wk
€52.50
Bilang ng mga empleyado
991
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Investing.com UK
·
6 oras ang nakalipas
Ptc Therapeutics stock hits 52-week low at $61.20 By Investing.com
Investing.com
·
15 oras ang nakalipas
PTC Therapeutics director Glenn Steele sells $781,920 in shares
Investing.com Canada
·
2 araw ang nakalipas
Form 144 PTC THERAPEUTICS For: 10 October By Investing.com
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Tungkol sa PTC Therapeutics, Inc.
CEOMatthew B. Klein
Mga Empleyado991
ItinatagEne 1, 1998
HeadquartersWarren, New Jersey, Estados Unidos
Sektor-
Websiteptcbio.com